Loading...
PHAR logo

Pharming Group N.V.NasdaqGM:PHAR Stock Report

Market Cap US$1.3b
Share Price
US$18.72
n/a
1Y99.6%
7D9.0%
Portfolio Value
​
View

Pharming Group N.V.

NasdaqGM:PHAR Stock Report

Market Cap: US$1.3b

Pharming Group (PHAR) Stock Overview

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. More details

PHAR fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance2/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 80% below our estimate of its fair value

Earnings are forecast to grow 42.7% per year

Became profitable this year

Trading at good value compared to peers and industry

Risk Analysis

Large one-off items impacting financial results


PHAR Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Pharming Group N.V. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Pharming Group
Historical stock prices
Current Share Price€18.72
52 Week High€19.05
52 Week Low€7.50
Beta0.16
1 Month Change14.99%
3 Month Change30.18%
1 Year Change99.57%
3 Year Change29.91%
5 Year Change27.52%
Change since IPO12.10%

Recent News & Updates

Recent updates

Pharming Group: Small Dutch Company With Strong Revenues

Apr 01

Pharming's rare immunodeficiency disorder drug gets FDA priority review

Sep 28

Pharming gets EMA panel nod for accelerated review of leniolisib for rare immunodeficiency disorder

Aug 01

Shareholder Returns

PHARUS BiotechsUS Market
7D9.0%-1.4%0.2%
1Y99.6%27.9%16.9%

Return vs Industry: PHAR exceeded the US Biotechs industry which returned 28.4% over the past year.

Return vs Market: PHAR exceeded the US Market which returned 18.7% over the past year.

Price Volatility

Is PHAR's price volatile compared to industry and market?
PHAR volatility
PHAR Average Weekly Movement10.6%
Biotechs Industry Average Movement11.3%
Market Average Movement6.5%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.0%

Stable Share Price: PHAR has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: PHAR's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1988404Fabrice Chouraquiwww.pharming.com

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Pharming Group N.V. Fundamentals Summary

How do Pharming Group's earnings and revenue compare to its market cap?
PHAR fundamental statistics
Market capUS$1.25b
Earnings (TTM)US$382.00k
Revenue (TTM)US$362.27m
3,283x
P/E Ratio
3.5x
P/S Ratio

Is PHAR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHAR income statement (TTM)
RevenueUS$362.27m
Cost of RevenueUS$36.58m
Gross ProfitUS$325.70m
Other ExpensesUS$325.31m
EarningsUS$382.00k

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

Mar 12, 2026

Earnings per share (EPS)0.00056
Gross Margin89.90%
Net Profit Margin0.11%
Debt/Equity Ratio37.2%

How did PHAR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/14 23:46
End of Day Share Price 2026/01/14 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharming Group N.V. is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John SavinEdison Investment Research
Simon ScholesFirst Berlin Equity Research GmbH
Joseph PantginisH.C. Wainwright & Co.